The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress 2024.

中文翻译：

---

Finerenone 改善 HFmrEF 和 HFpEF 的结局


根据 2024 年 ESC 大会上公布的调查结果，非甾体盐皮质激素受体拮抗剂 finerenone 可降低射血分数轻度降低或射血分数保留的心力衰竭患者出现不良后果的风险。